Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography - PubMed (original) (raw)

Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography

Daniel Wacker et al. J Am Chem Soc. 2010.

Abstract

G protein-coupled receptors (GPCRs) represent a large fraction of current pharmaceutical targets, and of the GPCRs, the beta(2) adrenergic receptor (beta(2)AR) is one of the most extensively studied. Previously, the X-ray crystal structure of beta(2)AR has been determined in complex with two partial inverse agonists, but the global impact of additional ligands on the structure or local impacts on the binding site are not well-understood. To assess the extent of such ligand-induced conformational differences, we determined the crystal structures of a previously described engineered beta(2)AR construct in complex with two inverse agonists: ICI 118,551 (2.8 A), a recently described compound (2.8 A) (Kolb et al, 2009), and the antagonist alprenolol (3.1 A). The structures show the same overall fold observed for the previous beta(2)AR structures and demonstrate that the ligand binding site can accommodate compounds of different chemical and pharmacological properties with only minor local structural rearrangements. All three compounds contain a hydroxy-amine motif that establishes a conserved hydrogen bond network with the receptor and chemically diverse aromatic moieties that form distinct interactions with beta(2)AR. Furthermore, receptor ligand cross-docking experiments revealed that a single beta(2)AR complex can be suitable for docking of a range of antagonists and inverse agonists but also indicate that additional ligand-receptor structures may be useful to further improve performance for in-silico docking or lead-optimization in drug design.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Structural comparison of the ligand binding sites in the (a) ICIβ2AR-t4l, (b) 2β2AR-t4l and (c) Alpβ2AR-t4l crystal structures. The ligands 1 (ICI 118,551), 2 and 3 (alprenolol) are colored in darker shades of orange, green and blue, respectively, while residues around the binding site are colored in lighter shades and labeled. Hydrogen bonds are depicted as black dotted lines. Chemical structures of compounds are shown in boxes.

Figure 2

Figure 2

Conserved overall fold of the ICIβ2AR-t4l, 2β2AR-t4l and Alpβ2AR-t4l structures compared to Timβ2AR-t4l and Carβ2AR-t4l. (a) Superimposition of all β2AR-t4l crystal structures determined to date (t4l omitted); ICIβ2AR-t4l (yellow), 2β2AR-t4l (green), Alpβ2AR-t4l (blue), Timβ2AR-t4l (magenta) and Carβ2AR-t4l (grey) (b) Close view of the ligand binding site showing the conserved binding of the hydroxy-amine motif and the differences in the aromatic system moieties. Compounds are shown as sticks and surrounding residue side chains are shown as lines. Superscripts indicate the Ballesteros-Weinstein numbering convention.

Similar articles

Cited by

References

    1. Audet M, Bouvier M. Nat Chem Biol. 2008;4:397. - PubMed
    1. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. Science. 2007;318:1258. - PMC - PubMed
    1. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, Velasquez J, Kuhn P, Stevens RC. Structure. 2008;16:897. - PMC - PubMed
    1. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF. Nature. 2008;454:486. - PMC - PubMed
    1. Katritch V, Reynolds KA, Cherezov V, Hanson MA, Roth CB, Yeager M, Abagyan R. J Mol Recognit. 2009;22:307. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources